Table 2. Therapeutic antibodies in Phase 2/3 or Phase 3 clinical studies of cancer indications.
| Sponsoring company | INN or code name | Molecular type | Target(s) | Current phase | Phase 2/3 or 3 indications |
|---|---|---|---|---|---|
| Active Biotech | Naptumomab estafenatox, ABR-217620 |
Murine Fab immunotoxin | 5T4 | Phase 2/3 | Renal cell carcinoma |
| Amgen | Rilotumumab | Human IgG2 | HGF/SF | Phase 3 | Gastric or gastresophageal junction adenocarcinoma |
| Morphotek | Farletuzumab | Humanized IgG1 | Folate receptor α | Phase 3 | Ovarian cancer |
| Bristol-Myers Squibb, Abbott | Elotuzumab | Humanized IgG1 | CD2 | Phase 3 | Multiple myeloma |
| Pfizer, UCB | Inotuzumab ozogamicin | Humanized IgG4 ADC | CD22 | Phase 3 | ALL; NHL |
| AstraZeneca* | Moxetumomab pasudotox, CAT-8015 |
Murine Fv immunotoxin | CD22 | Phase 3 | Hairy cell leukemia |
| ImClone Systems | Necitumumab | Human IgG1 | EGFR | Phase 3 | NSCL cancer |
| Bristol-Myers Squibb | Nivolumab, BMS-936558 |
Human IgG4 | PD1 | Phase 3 | NSCL cancer, renal cell carcinoma, melanoma |
| Genentech | Onartuzumab | Humanized IgG1 Fab-Fc | cMet | Phase 3 | NSCL cancer, gastric cancer |
| CIMAB; Laboratorio Elea S.A.C.I.F. y A | Racotumomab | Murine | GM3 | Phase 3 | NSCL cancer |
Note: Table compiled from information available as of April 25, 2013. *In-licensed; National Cancer Institute is sponsoring the Phase 3 study in hairy cell leukemia patients. Abbreviations: ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; HGF/SF, hepatocyte growth factor/ scatter factor; NHL, non-Hodgkin lymphoma; NSCL, non-small cell lung; VEGFR2, vascular endothelial growth factor receptor 2.